🚨New @portalresearch.org paper🚨 in JAMA Health Forum.
HIGHLIGHTS:
🔵 Biosimilars made up <2% of adalimumab use in 2023.
🔵 Net prices dropped by >40%...but the Humira list price increased.
Meaning: Abbvie payed confidential rebates to maintain Humira dominance. 💊🩺📊
📜 https://jamanetwork.com/journals/jama-health-forum/fullarticle/2827711
HIGHLIGHTS:
🔵 Biosimilars made up <2% of adalimumab use in 2023.
🔵 Net prices dropped by >40%...but the Humira list price increased.
Meaning: Abbvie payed confidential rebates to maintain Humira dominance. 💊🩺📊
📜 https://jamanetwork.com/journals/jama-health-forum/fullarticle/2827711
Comments